

Yongpeng Ge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8940467/publications.pdf>

Version: 2024-02-01

20
papers

375
citations

1305906

8
h-index

993246

17
g-index

20
all docs

20
docs citations

20
times ranked

452
citing authors

#	ARTICLE	IF	CITATIONS
1	Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies. <i>BMC Pulmonary Medicine</i> , 2022, 22, 14.	0.8	9
2	Clinical heterogeneities and prognoses of patients with myositis specific antibody negative dermatomyositis: a retrospective study in China. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 284-291.	0.4	2
3	The Clinical Phenotype of Chinese Patients With Autoimmune Pancreatitis Differs Significantly From Western Patients. <i>Frontiers in Medicine</i> , 2022, 9, 771784.	1.2	1
4	Thromboembolic events in idiopathic inflammatory myopathy: a retrospective study in China. <i>Clinical Rheumatology</i> , 2022, , 1.	1.0	2
5	Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210981.	1.1	5
6	Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. <i>Clinical Rheumatology</i> , 2021, 40, 2311-2317.	1.0	28
7	The effects of infliximab in treating idiopathic inflammatory myopathies: A review article. <i>Dermatologic Therapy</i> , 2021, 34, e14976.	0.8	6
8	Interstitial Lung Disease Is a Major Characteristic of Patients Who Test Positive for Anti-PM/Scl Antibody. <i>Frontiers in Medicine</i> , 2021, 8, 778211.	1.2	6
9	Clinical heterogeneities and prognoses of patients with myositis specific antibody negative dermatomyositis: a retrospective study in China. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
10	Coexistence of Axial Spondyloarthritis and Idiopathic Inflammatory Myopathy. <i>Case Reports in Rheumatology</i> , 2020, 2020, 1-4.	0.2	0
11	Interstitial lung disease is a major characteristic of anti-KS associated ant-synthetase syndrome. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232096841.	1.1	11
12	Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity. <i>Mediators of Inflammation</i> , 2020, 2020, 1-8.	1.4	4
13	Tracheobronchial amyloidosis in primary SjÅrfgren syndrome. <i>Medicine (United States)</i> , 2020, 99, e22942.	0.4	1
14	Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome. <i>Clinical Rheumatology</i> , 2020, 39, 2417-2424.	1.0	14
15	The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. <i>Clinical Rheumatology</i> , 2019, 38, 2171-2179.	1.0	41
16	Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. <i>Scientific Reports</i> , 2017, 7, 188.	1.6	65
17	The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis. <i>Clinical Rheumatology</i> , 2016, 35, 2715-2721.	1.0	19
18	Clinical Characteristics of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Antibodies in Chinese Patients with Idiopathic Inflammatory Myopathies. <i>PLoS ONE</i> , 2015, 10, e0141616.	1.1	66

#	ARTICLE	IF	CITATIONS
19	The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. <i>Clinical Rheumatology</i> , 2015, 34, 2097-2103.	1.0	47
20	Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. <i>Clinical Rheumatology</i> , 2015, 34, 99-105.	1.0	48